Zacks Research Lowers Earnings Estimates for Avanos Medical

Avanos Medical, Inc. (NYSE:AVNS) – Equities research analysts at Zacks Research dropped their FY2026 EPS estimates for shares of Avanos Medical in a note issued to investors on Tuesday, May 26th. Zacks Research analyst Team now forecasts that the company will post earnings of $1.06 per share for the year, down from their previous estimate of $1.07. Zacks Research currently has a “Strong Sell” rating on the stock. The consensus estimate for Avanos Medical’s current full-year earnings is $1.07 per share.

Avanos Medical (NYSE:AVNS) last issued its earnings results on Tuesday, May 5th. The company reported $0.22 EPS for the quarter, beating the consensus estimate of $0.16 by $0.06. The company had revenue of $182.20 million during the quarter, compared to analysts’ expectations of $170.00 million. Avanos Medical had a negative net margin of 10.39% and a positive return on equity of 5.39%. The business’s revenue for the quarter was up 8.8% compared to the same quarter last year. During the same period in the previous year, the company earned $0.26 EPS.

Several other equities analysts have also recently commented on AVNS. Weiss Ratings upgraded shares of Avanos Medical from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, April 22nd. Wall Street Zen cut shares of Avanos Medical from a “buy” rating to a “hold” rating in a research report on Saturday, April 18th. Two equities research analysts have rated the stock with a Sell rating, According to MarketBeat.com, Avanos Medical currently has a consensus rating of “Sell”.

Avanos Medical Price Performance

Shares of NYSE:AVNS opened at $24.73 on Wednesday. The firm has a 50 day moving average of $20.11 and a 200-day moving average of $15.23. The stock has a market capitalization of $1.16 billion, a PE ratio of -15.36 and a beta of 1.58. The company has a current ratio of 2.48, a quick ratio of 1.40 and a debt-to-equity ratio of 0.11. Avanos Medical has a 12 month low of $9.30 and a 12 month high of $24.91.

Hedge Funds Weigh In On Avanos Medical

A number of institutional investors have recently added to or reduced their stakes in the stock. Federated Hermes Inc. increased its position in Avanos Medical by 2.8% during the 4th quarter. Federated Hermes Inc. now owns 25,774 shares of the company’s stock worth $289,000 after purchasing an additional 691 shares in the last quarter. PNC Financial Services Group Inc. increased its position in Avanos Medical by 15.5% during the 1st quarter. PNC Financial Services Group Inc. now owns 6,317 shares of the company’s stock worth $89,000 after purchasing an additional 846 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Avanos Medical by 4.3% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,955 shares of the company’s stock worth $386,000 after purchasing an additional 1,121 shares in the last quarter. Azzad Asset Management Inc. ADV increased its position in Avanos Medical by 3.0% during the 3rd quarter. Azzad Asset Management Inc. ADV now owns 43,230 shares of the company’s stock worth $500,000 after purchasing an additional 1,240 shares in the last quarter. Finally, EverSource Wealth Advisors LLC grew its holdings in Avanos Medical by 132.6% during the 4th quarter. EverSource Wealth Advisors LLC now owns 2,496 shares of the company’s stock worth $28,000 after acquiring an additional 1,423 shares during the last quarter. 95.17% of the stock is currently owned by institutional investors and hedge funds.

About Avanos Medical

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.